MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered donor cells aim to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study tests a new way to prepare donor stem cells (called Orca-Q) for people with blood cancers like leukemia or MDS who need a transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells with fewer complications. About 300 partici…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New cell therapy aims to make mismatched donor transplants safer for blood cancer patients
Disease control Recruiting nowThis early-phase trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in 24 adults with advanced blood cancers (like leukemia or MDS) receiving stem cell transplants from partially matched donors. The main goal is to se…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cell therapy aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can impr…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo targets hard-to-treat leukemias in early trial
Disease control Recruiting nowThis study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and se…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to beat tough childhood leukemia
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study will enroll about 6,000 participants an…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemias
Disease control Recruiting nowThis study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New stem cell transplant trial offers hope for blood cancer patients
Disease control Recruiting nowThis study tests a stem cell transplant from half-matched (haploidentical) donors for people with various blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare their body. The goal is to replace diseased bone marrow with healthy don…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at childhood leukemia in new trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults (up to age 21) with certain types of leukemia or related blood cancers that have come back or not responded to standard therapy. The treatment involves collecting the patient's own…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Supercharged immune cells take on relapsed leukemia
Disease control Recruiting nowThis early-phase trial tests a new immunotherapy for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor T cells designed to recognize and attack a protein called HA-1 found …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could removing certain immune cells prevent a deadly transplant complication?
Disease control Recruiting nowThis study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo attack on tough blood cancers: chemo plus transplant shows promise
Disease control Recruiting nowThis study tests a new approach for adults with aggressive blood cancers (like AML) that are likely to return after standard treatment. Participants receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and low-dose radiation, followed immediately by a stem cell …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo aims to stop leukemia relapse after transplant
Disease control Recruiting nowThis study looks at whether menin inhibitors can help prevent leukemia from coming back in patients who have had a stem cell transplant. About 20 adults with certain genetic types of acute leukemia will take these drugs as maintenance therapy. Researchers will track how many pati…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for tough leukemia: experimental drug combo enters human testing
Disease control Recruiting nowThis study tests a new drug called lisaftoclax, alone or combined with other medicines, in people with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check safety and find the best dose. About 682 adults will take part across multip…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Second chance: cord blood transplant trial for relapsed blood cancers
Disease control Recruiting nowThis phase 2 trial tests an optimized cord blood transplant for 35 patients with high-risk blood cancers (like leukemia) who relapsed after their first stem cell transplant. Participants receive chemotherapy followed by a cord blood infusion, plus drugs to prevent rejection. The …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to boost leukemia remission
Disease control Recruiting nowThis study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will take…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for babies with aggressive leukemia: international trial launches
Disease control Recruiting nowThis study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants from around the world will…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy aims to stop leukemia from coming back after transplant
Disease control Recruiting nowThis study tests whether adding a precise, targeted form of radiation to the standard chemotherapy and stem cell transplant can kill more cancer cells in the bone marrow and reduce the chance of relapse. About 27 adults with acute leukemia or myelodysplastic syndrome (MDS) will r…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for tough leukemias: experimental pill targets genetic weakness
Disease control Recruiting nowThis study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New targeted pill hopes to tackle tough leukemias
Disease control Recruiting nowThis early-stage trial is testing an oral drug called BY002 in 18 adults with relapsed or refractory acute leukemia that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shr…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New stem cell transplant method shows promise for kids with tough blood cancers
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for tough leukemia: capivasertib combo enters human trials
Disease control Recruiting nowThis study tests whether adding the experimental drug capivasertib to a standard treatment (venetoclax plus low-intensity chemotherapy) is safe and effective for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to prior …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for kids with tough leukemias: experimental combo trial opens
Disease control Recruiting nowThis phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new type of immune therapy called CD70-CAR T cells in children and young adults up to age 21 with blood cancers that have come back or not responded to treatment. The therapy involves taking the patient's own immune cells, engineering them to recogn…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cord blood transplant method aims to beat high-risk blood cancers
Disease control Recruiting nowThis study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New oral drug MRX-2843 tested in Hard-to-Treat leukemias
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called MRX-2843 in adolescents and adults whose acute leukemia (AML, ALL, or mixed phenotype) has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and s…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immune booster: donor NK cells aim to stop leukemia return after transplant
Disease control Recruiting nowThis clinical trial tests whether infusions of donor natural killer (NK) cells, given before and after a stem cell transplant, can safely prevent leukemia from coming back in children and young adults with hard-to-treat acute leukemia. The study enrolls 15 patients aged 0 to 25 w…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cord blood transplant recipe aims to beat tough blood cancers
Disease control Recruiting nowThis study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 15:21 UTC
-
New screening trial aims to match kids with relapsed leukemia to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study maps Kids' leukemia to match best treatment
Knowledge-focused Recruiting nowThis study enrolls children and teens (ages 1-18) newly diagnosed with certain types of leukemia or lymphoma. The main goal is to gather enough information from their tumor samples to figure out their risk of the cancer coming back, so they can be placed into the right treatment …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE4 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Scientists hunt for smarter treatments for kids with leukemia
Knowledge-focused Recruiting nowThis study is collecting genetic and drug sensitivity data from 300 children with leukemia to better understand why some cases relapse and how to target them more precisely. Researchers will analyze tumor DNA, gene activity, and test drugs on patient cells in the lab. The goal is…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC